AstraZeneca to Make $2 Billion Strategic Investment in Summit Therapeutics

Shares of Summit Therapeutics (NASDAQ:SMMT) surged 15% in extended trading Monday after pharmaceutical major AstraZeneca (NYSE:AZN) agreed to a $2.0 billion strategic equity investment in the company. The deal is designed to fund a broad collaboration focused on Summit's lead cancer therapy candidate.

Deal Details

AstraZeneca will acquire convertible preferred shares in Summit at a price equivalent to $18.36 per common share, according to a company announcement. This price represents a 10% premium over Summit's five-day volume-weighted average price.

The capital infusion provides Summit with significant funding to accelerate its global clinical development programs. For AstraZeneca, the transaction secures a substantial strategic position in a promising next-generation cancer therapy.

Strategic Collaboration

The investment underpins a partnership to develop Summit’s flagship asset, the bispecific antibody ivonescimab, in combination with AstraZeneca’s extensive oncology portfolio. The companies have established an initial clinical trial to evaluate ivonescimab alongside sonesitatug vedotin, an investigational antibody-drug conjugate from AstraZeneca targeting gastrointestinal cancers.

Ad

Under the trial agreement, the two firms will share study costs, though AstraZeneca will act as the sponsor. Both companies will retain full commercial and development rights to their respective assets. The partners also signed a non-binding memorandum of understanding to explore pairing ivonescimab with other drugs in AstraZeneca's pipeline.

Context and Market Impact

The deal provides both financial support and significant validation for Summit as it approaches a key regulatory milestone. The U.S. Food and Drug Administration (FDA) is currently reviewing the company's Biologics License Application for ivonescimab for the treatment of non-small cell lung cancer.

The FDA has set a target decision date, known as the Prescription Drug User Fee Act (PDUFA) date, for November 14, 2026. The capital from AstraZeneca will help Summit advance its late-stage trials in other cancers, including colorectal, head and neck, and bladder, as it prepares for potential commercialization.